Genetic Modifiers of ALS: The Impact of Chromogranin B P413L in a Bulgarian ALS Cohort
Genes · 2024
DOI: 10.3390/genes15091197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Ivan Tourtourikov und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Chemistry and Biochemistry, Medical University of Sofia, 1431 Sofia, Bulgaria. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Genetic Predisposition to Disease, Chromogranin B. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Sofia, European Union-NextGenerationEU, Medical University Sofia, Bulgaria.
Abstract (Originalsprache)
This study investigated the role of the CHGB P413L variant (rs742710) in sporadic amyotrophic lateral sclerosis (sALS) within the Bulgarian population. We analyzed 150 patients with sALS (85 male and 65 female) for the presence of this variant, its potential impact on disease susceptibility, and age of onset. Genotyping was performed using PCR amplification and direct Sanger sequencing. Statistical analyses included comparisons with control data from GnomAD v2.1.1, one-way ANOVA, and Kaplan–Meier survival analysis. Results revealed a higher frequency of the minor T allele in patients with sALS compared to all control groups and a statistically significant increase in carrier genotypes compared to non-Finnish Europeans (χ2 = 15.4572, p = 0.000440). However, the impact on age of onset was less clear, with no statistically significant differences observed across genotypes or between carriers and non-carriers of the T allele. Kaplan–Meier analysis suggested a potential 2.5-year-earlier onset in T allele carriers, but the small sample size of carriers limits the reliability of this finding. Our study provides evidence for an association between the CHGB P413L variant and sALS susceptibility in the Bulgarian population, while its effect on age of onset remains uncertain, highlighting the need for further research in larger, diverse cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Chemistry and Biochemistry, Medical University of Sofia, 1431 Sofia, Bulgaria.
- Genetic Medico Diagnostic Laboratory Genica, 1612 Sofia, Bulgaria.
- Department of Neurology, Faculty of Medicine, Medical University of Sofia, 1431 Sofia, Bulgaria.
- Department of Neurology, Clinic of Nervous Diseases, Medical University of Sofia, UMBAL Aleksandrovska, 1431 Sofia, Bulgaria.
- Department of Cognitive Science and Psychology, New Bulgarian University, 1618 Sofia, Bulgaria.
ORCID-Profile: Ivan Tourtourikov, Teodora Chamova, Vanyo Mitev
Förderung
- Medical University of Sofia
- European Union-NextGenerationEU
- Medical University Sofia, Bulgaria
- European Union Next Generation EU through the Bulgarian National Recovery and Resilience Plan
- National Science Fund of Bulgaria (BNSF)
Zitieren
APA
Tourtourikov, I., Todorov, T., Angelov, T., Chamova, T., Tournev, I., Mitev, V., & Todorova, A. (2024). Genetic Modifiers of ALS: The Impact of Chromogranin B P413L in a Bulgarian ALS Cohort. Genes. https://doi.org/10.3390/genes15091197
Vancouver
Tourtourikov I, Todorov T, Angelov T, Chamova T, Tournev I, Mitev V, et al. Genetic Modifiers of ALS: The Impact of Chromogranin B P413L in a Bulgarian ALS Cohort. Genes. 2024. doi:10.3390/genes15091197
BibTeX
@article{Tourtourikov2024,
author = {Tourtourikov, Ivan and Todorov, Tihomir and Angelov, Teodor and Chamova, Teodora and Tournev, Ivailo and Mitev, Vanyo and Todorova, Albena},
title = {Genetic Modifiers of ALS: The Impact of Chromogranin B P413L in a Bulgarian ALS Cohort},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15091197}
}
EUVIMED